Cheskin LJ, Hill C, Adam A, Fayad L, Dunlap M, Badurdeen D, Koller K, Bunyard L, Frutchey R, Al-Grain H, Kahan S, Hedjoudje A,
Khashab MA, Kalloo AN, Kumbhari V.
Gastrointest Endosc. 2019
Abstract
BACKGROUND AND AIMS:
Endoscopic sleeve gastroplasty (ESG) is a safe and effective minimally invasive bariatric procedure. This study compared
weight loss in patients undergoing ESG with that of matched patients undergoing high-intensity diet and lifestyle therapy
(HIDLT).

Obes Surg. 2019 Jul;29(7):2287-2298. doi: 10.1007/s11695-019-03865-w.
BACKGROUND AND AIMS:
Novel endoscopic procedures (endoscopic sleeve gastroplasty (ESG), AspireAssist (AA), and primary obesity surgery
endolumenal (POSE)) have been developed for treatment of obesity. We aimed to conduct a systematic review and metaanalysis
to evaluate and compare the efficacy of these three endoscopic procedures.

BACKGROUND AND AIMS:
Endoscopic sleeve gastroplasty (ESG) reduces the gastric lumen to a size comparable with that of
laparoscopic sleeve gastrectomy (LSG). However, there is a paucity of research comparing outcomes between the 2
procedures. Our study compared the 6-month weight loss outcomes and adverse events of ESG with LSG in a case-matched
cohort.

How Do They Compare?
Abstract
BACKGROUND:
Endoscopic sleeve gastroplasty (ESG) is a novel endobariatric procedure. Initial studies demonstrated an association of ESG
with weight loss and improvement of obesity-related comorbidities. Our aim was to compare ESG to
laparoscopic sleeve gastrectomy (LSG) and laparoscopic adjustable gastric banding (LAGB).